MX2021003550A - Formas cristalinas novedosas de sugammadex. - Google Patents

Formas cristalinas novedosas de sugammadex.

Info

Publication number
MX2021003550A
MX2021003550A MX2021003550A MX2021003550A MX2021003550A MX 2021003550 A MX2021003550 A MX 2021003550A MX 2021003550 A MX2021003550 A MX 2021003550A MX 2021003550 A MX2021003550 A MX 2021003550A MX 2021003550 A MX2021003550 A MX 2021003550A
Authority
MX
Mexico
Prior art keywords
sugammadex
crystalline form
form type
crystalline forms
novel crystalline
Prior art date
Application number
MX2021003550A
Other languages
English (en)
Inventor
Patrick Larpent
Paolo Avalle
Lorenzo Codan
Jochen Schöll
Original Assignee
Werthenstein Biopharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werthenstein Biopharma Gmbh filed Critical Werthenstein Biopharma Gmbh
Publication of MX2021003550A publication Critical patent/MX2021003550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención proporciona formas cristalinas novedosas de sugammadex, designadas en la presente como forma cristalina Tipo 1 de sugammadex, forma cristalina Tipo 2 de sugammadex, forma cristalina Tipo 3 de sugammadex, forma cristalina Tipo 8 de sugammadex, y forma cristalina Tipo 9 de sugammadex, composiciones farmacéuticas de las mismas, y métodos para su uso en la reversión del bloqueo neuromuscular inducido por bromuro de rocuronio o por bromuro de vecuronio en adultos que se sometieron a cirugía.
MX2021003550A 2018-09-27 2019-09-25 Formas cristalinas novedosas de sugammadex. MX2021003550A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737140P 2018-09-27 2018-09-27
PCT/EP2019/075823 WO2020064811A1 (en) 2018-09-27 2019-09-25 Novel crystalline forms of sugammadex

Publications (1)

Publication Number Publication Date
MX2021003550A true MX2021003550A (es) 2021-05-27

Family

ID=68072397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003550A MX2021003550A (es) 2018-09-27 2019-09-25 Formas cristalinas novedosas de sugammadex.

Country Status (10)

Country Link
US (1) US20220049023A1 (es)
EP (1) EP3856791A1 (es)
JP (1) JP2022501489A (es)
KR (1) KR20210087934A (es)
CN (1) CN112752770A (es)
AU (1) AU2019345980A1 (es)
BR (1) BR112021005526A2 (es)
CA (1) CA3112872A1 (es)
MX (1) MX2021003550A (es)
WO (1) WO2020064811A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AU2016359431B2 (en) * 2015-11-25 2020-10-22 Fresenius Kabi Ipsum S.R.L. Crystalline forms of per-chloro-gamma-cyclodextrines
EP3380530B1 (en) * 2015-11-25 2020-10-07 Fresenius Kabi iPSUM S.r.l. An improved process for the preparation of sugammadex and its intermediates
EP3733717A3 (en) * 2016-03-22 2020-12-30 Fresenius Kabi iPSUM S.r.l. An improved process for the preparation of sugammadex
US20180016359A1 (en) * 2016-06-29 2018-01-18 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Sugammadex preparation and purification method
CN107400182A (zh) * 2017-06-26 2017-11-28 江苏悦兴医药技术有限公司 舒更葡糖钠晶型a及其制备方法和用途
US10336835B2 (en) * 2017-08-23 2019-07-02 Formosa Laboratories, Inc. Polymorphs of sugammadex and process for preparation of sugammadex
CN107892727B (zh) * 2017-11-27 2019-12-24 合肥博思科创医药科技有限公司 一种舒更葡糖钠的纯化方法
WO2019193198A1 (en) * 2018-04-06 2019-10-10 Synthon B.V. Purification of sugammadex
CN109053933B (zh) * 2018-08-01 2020-10-23 合肥博思科创医药科技有限公司 一种无定型舒更葡糖钠的制备方法
WO2020028448A1 (en) * 2018-08-02 2020-02-06 Pliva Hrvatska D.O.O. Solid state forms of sugammadex sodium

Also Published As

Publication number Publication date
BR112021005526A2 (pt) 2021-06-29
CN112752770A (zh) 2021-05-04
JP2022501489A (ja) 2022-01-06
WO2020064811A1 (en) 2020-04-02
US20220049023A1 (en) 2022-02-17
AU2019345980A1 (en) 2021-04-08
KR20210087934A (ko) 2021-07-13
CA3112872A1 (en) 2020-04-02
EP3856791A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MX2021009673A (es) Moduladores de ror-gamma.
MY194313A (en) Substituted chromanes and method of use
MX2018000688A (es) Triciclicos sustituidos y metodo para usarlos.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MD3319612T2 (ro) Oxisteroli și metode de utilizare a acestora
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021001786A (es) Antagonistas de integrina.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12019500822A1 (en) Crystalline forms of eravacycline
CY1121707T1 (el) Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων
PH12016501483B1 (en) P-substituted asymmetric ureas and medical uses thereof
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2021000841A (es) Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
CY1123185T1 (el) Παραγωγα ινδολιου